PATENT CLAIM ANALYSIS

Application Number: 15874299
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Claim (Index 8):
The compound of  claim 1 , wherein R 7  is C 1-6  alkyl, phenyl, 5- or 6-membered heteroaryl, C 3-6  cycloalkyl or 4- to 6-membered heterocycloalkyl, each of which is optionally substituted with from 1-2 members selected from halo, C 1-4  alkyl, CN, C 1-4  haloalkyl, C 1-4  alkoxy, phenyl, C 3-6  cycloalkyl, 5- or 6-membered heteroaryl, or 4- to 6-membered heterocycloalkyl.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15047892', '15047903', '15408001', '14132653', '15712290']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.790868821373752
- 35 USC 102 Novelty (BERT): 0.5809171410329108
- Combined Prediction Score: 0.769873653339668
- Mean Citation Score: 439.730804
- Max Citation Score: 488.92752
- Similarity Product: 391.5346858678722

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test